News Quantified


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Altimmune, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Altimmune, Inc. (ALT) Class Action

Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 - ALT

Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]

Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at JMP Securities from $25.00 to $24.00. They now have a "market outperform" rating on the stock.

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

5/9/2024

07:00 am

ALT

8.1%

BEAT

3/27/2024

07:00 am

ALT

1.9%

MISS

11/7/2023

07:00 am

ALT

4.7%

BEAT

8/10/2023

07:00 am

ALT

1.3%

BEAT

Form 10-Q Altimmune, Inc. For: Mar 31

Form 8-K Altimmune, Inc. For: May 09

Form SC 13G/A Altimmune, Inc. Filed by: STATE STREET CORP

Form S-8 Altimmune, Inc.

Form 10-K Altimmune, Inc. For: Dec 31

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}